Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer

ABSTRACT

The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

This application is a divisional of U.S. application Ser. No.13/500,241, which is a National Stage filed on Apr. 4, 2012, which is a371 of International Application No. PCT/US2010/051907 filed Oct. 8,2010, which claims the benefit of U.S. Provisional Application No.61/249,803 filed Oct. 8, 2009.

FIELD OF THE INVENTION

The present invention relates to a method of treating cancer in a mammaland to combinations useful in such treatment. In particular, the methodrelates to a novel combination comprising the B-Raf inhibitor:N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, and the Akt inhibitor:N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, pharmaceuticalcompositions comprising the same, and methods of using such combinationsin the treatment of cancer.

BACKGROUND OF THE INVENTION

Effective treatment of hyperproliferative disorders including cancer isa continuing goal in the oncology field. Generally, cancer results fromthe deregulation of the normal processes that control cell division,differentiation and apoptotic cell death. Apoptosis (programmed celldeath) plays essential roles in embryonic development and pathogenesisof various diseases, such as degenerative neuronal diseases,cardiovascular diseases and cancer. One of the most commonly studiedpathways, which involves kinase regulation of apoptosis, is cellularsignaling from growth factor receptors at the cell surface to thenucleus (Crews and Erikson, Cell, 74:215-17, 1993).

An important large family of enzymes is the protein kinase enzymefamily. There are about 500 different known protein kinases. Proteinkinases serve to catalyze the phosphorylation of an amino acid sidechain in various proteins by the transfer of the γ-phosphate of theATP-Mg²⁺ complex to said amino acid side chain. These enzymes controlthe majority of the signaling processes inside cells, thereby governingcell function, growth, differentiation and destruction (apoptosis)through reversible phosphorylation of the hydroxyl groups of serine,threonine and tyrosine residues in proteins. Studies have shown thatprotein kinases are key regulators of many cell functions, includingsignal transduction, transcriptional regulation, cell motility, and celldivision. Several oncogenes have also been shown to encode proteinkinases, suggesting that kinases play a role in oncogenesis. Theseprocesses are highly regulated, often by complex intermeshed pathwayswhere each kinase will itself be regulated by one or more kinases.Consequently, aberrant or inappropriate protein kinase activity cancontribute to the rise of disease states associated with such aberrantkinase activity including benign and malignant proliferative disordersas well as diseases resulting from inappropriate activation of theimmune and nervous systems. Due to their physiological relevance,variety and ubiquitousness, protein kinases have become one of the mostimportant and widely studied family of enzymes in biochemical andmedical research.

The protein kinase family of enzymes is typically classified into twomain subfamilies: Protein Tyrosine Kinases and Protein Serine/ThreonineKinases, based on the amino acid residue they phosphorylate. The proteinserine/threonine kinases (PSTK), includes cyclic AMP- and cyclicGMP-dependent protein kinases, calcium and phospholipid dependentprotein kinase, calcium- and calmodulin-dependent protein kinases,casein kinases, cell division cycle protein kinases and others. Thesekinases are usually cytoplasmic or associated with the particulatefractions of cells, possibly by anchoring proteins. Aberrant proteinserine/threonine kinase activity has been implicated or is suspected ina number of pathologies such as rheumatoid arthritis, psoriasis, septicshock, bone loss, many cancers and other proliferative diseases.Accordingly, serine/threonine kinases and the signal transductionpathways which they are part of are important targets for drug design.The tyrosine kinases phosphorylate tyrosine residues. Tyrosine kinasesplay an equally important role in cell regulation. These kinases includeseveral receptors for molecules such as growth factors and hormones,including epidermal growth factor receptor, insulin receptor, plateletderived growth factor receptor and others. Studies have indicated thatmany tyrosine kinases are transmembrane proteins with their receptordomains located on the outside of the cell and their kinase domains onthe inside. Much work is also in progress to identify modulators oftyrosine kinases as well.

Mitogen-activated protein (MAP) Kinase/extracellular signal-regulatedkinase (ERK) kinase (hereinafter referred to as MEK) is known to beinvolved in the regulation of cell proliferation as a kinase thatmediates Raf-MEK-ERK signal transduction pathway, and the Raf family(B-Raf, C-Raf etc.) activates the MEK family (MEK-1, MEK-2 etc.) and theMEK family activates the ERK family (ERK-1 and ERK-2).

Activation of Raf-MEK-ERK signal transduction pathway in cancer,particularly colorectal cancer, pancreatic cancer, lung cancer, breastcancer and the like, has been frequently observed.

Naturally occurring mutations of the B-Raf kinase that activate MAPKpathway signaling have been found in a large percentage of humanmelanomas (Davies (2002) supra) and thyroid cancers (Cohen et al J. Nat.Cancer Inst. (2003) 95(8) 625-627 and Kimura et al Cancer Res. (2003)63(7) 1454-1457). By virtue of the role played by the Raf family kinasesin these cancers and exploratory studies with a range of preclinical andtherapeutic agents, including one selectively targeted to inhibition ofB-Raf kinase activity (King A. J., et al., (2006) Cancer Res.66:11100-11105), it is generally accepted that inhibitors of Raf familykinases will be useful for the treatment of such cancers or othercondition associated with Raf kinase.

Apoptosis (programmed cell death) plays essential roles in embryonicdevelopment and pathogenesis of various diseases, such as degenerativeneuronal diseases, cardiovascular diseases and cancer. Recent work hasled to the identification of various pro- and anti-apoptotic geneproducts that are involved in the regulation or execution of programmedcell death. Expression of anti-apoptotic genes, such as Bcl2 orBcl-x_(L), inhibits apoptotic cell death induced by various stimuli. Onthe other hand, expression of pro-apoptotic genes, such as Bax or Bad,leads to programmed cell death (Adams et al. Science, 281:1322-1326(1998)). The execution of programmed cell death is mediated by caspase-1related proteinases, including caspase-3, caspase-7, caspase-8 andcaspase-9 etc (Thornberry et al. Science, 281:1312-1316 (1998)).

The phosphatidylinositol 3′-OH kinase (PI3K)/Akt/PKB pathway appearsimportant for regulating cell survival/cell death (Kulik et al. Mol.Cell. Biol. 17:1595-1606 (1997); Franke et al, Cell, 88:435-437 (1997);Kauffmann-Zeh et al. Nature 385:544-548 (1997) Hemmings Science,275:628-630 (1997); Dudek et al., Science, 275:661-665 (1997)). Survivalfactors, such as platelet derived growth factor (PDGF), nerve growthfactor (NGF) and insulin-like growth factor-1 (IGF-I), promote cellsurvival under various conditions by inducing the activity of PI3K(Kulik et al. 1997, Hemmings 1997). Activated PI3K leads to theproduction of phosphatidylinositol (3,4,5)-triphosphate (Ptdlns(3,4,5)-P3), which in turn binds to, and promotes the activation of, theserine/threonine kinase Akt, which contains a pleckstrin homology(PH)-domain (Franke et al Cell, 81:727-736 (1995); Hemmings Science,277:534 (1997); Downward, Curr. Opin. Cell Biol. 10:262-267 (1998),Alessi et al., EMBO J. 15: 6541-6551 (1996)). Specific inhibitors ofPI3K or dominant negative Akt/PKB mutants abolish survival-promotingactivities of these growth factors or cytokines. It has been previouslydisclosed that inhibitors of PI3K (LY294002 or wortmannin) blocked theactivation of Akt/PKB by upstream kinases. In addition, introduction ofconstitutively active PI3K or Akt/PKB mutants promotes cell survivalunder conditions in which cells normally undergo apoptotic cell death(Kulik et al. 1997, Dudek et al. 1997).

Analysis of Akt levels in human tumors showed that Akt2 is overexpressedin a significant number of ovarian (J. Q. Cheung et al. Proc. Natl.Acad. Sci. U.S.A. 89:9267-9271 (1992)) and pancreatic cancers (J. Q.Cheung et al. Proc. Natl. Acad. Sci. U.S.A. 93:3636-3641 (1996)).Similarly, Akt3 was found to be overexpressed in breast and prostatecancer cell lines (Nakatani et al. J. Biol. Chem. 274:21528-21532(1999). It was demonstrated that Akt-2 was over-expressed in 12% ofovarian carcinomas and that amplification of Akt was especially frequentin 50% of undifferentiated tumors, suggestion that Akt may also beassociated with tumor aggressiveness (Bellacosa, et al., Int. J. Cancer,64, pp. 280-285, 1995). Increased Akt1 kinase activity has been reportedin breast, ovarian and prostate cancers (Sun et al. Am. J. Pathol. 159:431-7 (2001)).

The tumor suppressor PTEN, a protein and lipid phosphatase thatspecifically removes the 3′ phosphate of Ptdlns(3,4,5)-P3, is a negativeregulator of the PI3K/Akt pathway (Li et al. Science 275:1943-1947(1997), Stambolic et al. Cell 95:29-39 (1998), Sun et al. Proc. Natl.Acad. Sci. U.S.A. 96:6199-6204 (1999)). Germline mutations of PTEN areresponsible for human cancer syndromes such as Cowden disease (Liaw etal. Nature Genetics 16:64-67 (1997)). PTEN is deleted in a largepercentage of human tumors and tumor cell lines without functional PTENshow elevated levels of activated Akt (Li et al. supra, Guldberg et al.Cancer Research 57:3660-3663 (1997), Risinger et al. Cancer Research57:4736-4738 (1997)).

These observations demonstrate that the PI3K/Akt pathway plays importantroles for regulating cell survival or apoptosis in tumorigenesis and/orcancer.

It would be useful to provide a novel therapy which provides moreeffective and/or enhanced treatment of an individual suffering theeffects of cancer.

SUMMARY OF THE INVENTION

One embodiment of this invention provides a combination comprising:

(i) a compound of Structure (I):

or a pharmaceutically acceptable salt thereof; and

(ii) a compound of Structure (II):

or a pharmaceutically acceptable salt thereof.

One embodiment of this invention provides a method of treating cancer ina human in need thereof which comprises the in vivo administration of atherapeutically effective amount of a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt, suitably the methanesulfonatesalt, thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to such human.

One embodiment of this invention provides a method of treating cancer ina human in need thereof which comprises the in vivo administration of atherapeutically effective amount of a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt, suitably the methanesulfonatesalt, thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to such human,

-   -   wherein the combination is administered within a specified        period, and    -   wherein the combination is administered for a duration of time.

One embodiment of this invention provides a method of treating cancer ina human in need thereof which comprises the in vivo administration of atherapeutically effective amount of a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt, suitably the methanesulfonatesalt, thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to such human,

-   -   wherein the compounds of the combination are administered        sequentially.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to combinations that exhibitantiproliferative activity. Suitably, the method relates to methods oftreating cancer by the co-administration ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt, suitably the methanesulfonatesalt, thereof, (hereinafter Compound A, or a pharmaceutically acceptablesalt, suitably the methanesulfonate salt, thereof,

which compound is represented by Structure I:

andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamideor a pharmaceutically acceptable salt thereof, (hereinafter Compound Bor a pharmaceutically acceptable salt thereof,

which compound is represented by Structure II:

Compound A is disclosed and claimed, along with pharmaceuticallyacceptable salts thereof, as being useful as an inhibitor of B-Rafactivity, particularly in treatment of cancer, in InternationalApplication No. PCT/US2009/042682, having an International filing dateof May 4, 2009, International Publication Number WO 2009/137391 and anInternational Publication date of Nov. 12, 2009, the entire disclosureof which is hereby incorporated by reference, Compound A is the compoundof Example 58. Compound A can be prepared as described in InternationalApplication No. PCT/US2009/042682.

Suitably, Compound A is in the form of a methanesulfonate salt. Thissalt form can be prepared by one of skill in the art from thedescription in International Application No. PCT/US2009/042682, havingan International filing date of May 4, 2009.

Compound B is disclosed and claimed, along with pharmaceuticallyacceptable salts thereof, as being useful as an inhibitor of AKTactivity, particularly in treatment of cancer, in InternationalApplication No. PCT/US2008/053269, having an International filing dateof Feb. 7, 2008; International Publication Number WO 2008/098104 and anInternational Publication date of Aug. 14, 2008, the entire disclosureof which is hereby incorporated by reference, Compound B is the compoundof example 224. Compound B can be prepared as described in InternationalApplication No. PCT/US2008/053269.

The administration of a therapeutically effective amount of thecombinations of the invention are advantageous over the individualcomponent compounds in that the combinations will provide one or more ofthe following improved properties when compared to the individualadministration of a therapeutically effective amount of a componentcompound: i) a greater anticancer effect than the most active singleagent, ii) synergistic or highly synergistic anticancer activity, iii) adosing protocol that provides enhanced anticancer activity with reducedside effect profile, iv) a reduction in the toxic effect profile, v) anincrease in the therapeutic window, or vi) an increase in thebioavailability of one or both of the component compounds.

The compounds of the invention may contain one or more chiral atoms, ormay otherwise be capable of existing as two enantiomers. Accordingly,the compounds of this invention include mixtures of enantiomers as wellas purified enantiomers or enantiomerically enriched mixtures. Also, itis understood that all tautomers and mixtures of tautomers are includedwithin the scope of Compound A, and pharmaceutically acceptable saltsthereof, and Compound B, and pharmaceutically acceptable salts thereof.

The compounds of the invention may form a solvate which is understood tobe a complex of variable stoichiometry formed by a solute (in thisinvention, Compound A or a salt thereof and/or Compound B or a saltthereof) and a solvent. Such solvents for the purpose of the inventionmay not interfere with the biological activity of the solute. Examplesof suitable solvents include, but are not limited to, water, methanol,dimethyl sulfoxide, ethanol and acetic acid. Suitably the solvent usedis a pharmaceutically acceptable solvent. Suitably the solvent used iswater.

The pharmaceutically acceptable salts of the compounds of the inventionare readily prepared by those of skill in the art.

Also, contemplated herein is a method of treating cancer using acombination of the invention where Compound A, or a pharmaceuticallyacceptable salt thereof, and/or Compound B or a pharmaceuticallyacceptable salt thereof are administered as pro-drugs. Pharmaceuticallyacceptable pro-drugs of the compounds of the invention are readilyprepared by those of skill in the art.

When referring to a dosing protocol, the term “day”, “per day” and thelike, refer to a time within one calendar day which begins at midnightand ends at the following midnight.

By the term “treating” and derivatives thereof as used herein, is meanttherapeutic therapy. In reference to a particular condition, treatingmeans: (1) to ameliorate or prevent the condition of one or more of thebiological manifestations of the condition, (2) to interfere with (a)one or more points in the biological cascade that leads to or isresponsible for the condition or (b) one or more of the biologicalmanifestations of the condition, (3) to alleviate one or more of thesymptoms, effects or side effects associated with the condition ortreatment thereof, or (4) to slow the progression of the condition orone or more of the biological manifestations of the condition.Prophylactic therapy is also contemplated thereby. The skilled artisanwill appreciate that “prevention” is not an absolute term. In medicine,“prevention” is understood to refer to the prophylactic administrationof a drug to substantially diminish the likelihood or severity of acondition or biological manifestation thereof, or to delay the onset ofsuch condition or biological manifestation thereof. Prophylactic therapyis appropriate, for example, when a subject is considered at high riskfor developing cancer, such as when a subject has a strong familyhistory of cancer or when a subject has been exposed to a carcinogen.

As used herein, the term “effective amount” means that amount of a drugor pharmaceutical agent that will elicit the biological or medicalresponse of a tissue, system, animal or human that is being sought, forinstance, by a researcher or clinician. Furthermore, the term“therapeutically effective amount” means any amount which, as comparedto a corresponding subject who has not received such amount, results inimproved treatment, healing, prevention, or amelioration of a disease,disorder, or side effect, or a decrease in the rate of advancement of adisease or disorder. The term also includes within its scope amountseffective to enhance normal physiological function.

By the term “combination” and derivatives thereof, as used herein ismeant either simultaneous administration or any manner of separatesequential administration of a therapeutically effective amount ofCompound A, or a pharmaceutically acceptable salt thereof, and CompoundB or a pharmaceutically acceptable salt thereof. Preferably, if theadministration is not simultaneous, the compounds are administered in aclose time proximity to each other. Furthermore, it does not matter ifthe compounds are administered in the same dosage form, e.g. onecompound may be administered topically and the other compound may beadministered orally. Suitably, both compounds are administered orally.

By the term “combination kit” as used herein is meant the pharmaceuticalcomposition or compositions that are used to administer Compound A, or apharmaceutically acceptable salt thereof, and Compound B, or apharmaceutically acceptable salt thereof, according to the invention.When both compounds are administered simultaneously, the combination kitcan contain Compound A, or a pharmaceutically acceptable salt thereof,and Compound B, or a pharmaceutically acceptable salt thereof, in asingle pharmaceutical composition, such as a tablet, or in separatepharmaceutical compositions. When the compounds are not administeredsimultaneously, the combination kit will contain Compound A, or apharmaceutically acceptable salt thereof, and Compound B, or apharmaceutically acceptable salt thereof, in separate pharmaceuticalcompositions. The combination kit can comprise Compound A, or apharmaceutically acceptable salt thereof, and Compound B, or apharmaceutically acceptable salt thereof, in separate pharmaceuticalcompositions in a single package or in separate pharmaceuticalcompositions in separate packages.

In one aspect there is provided a combination kit comprising thecomponents:

Compound A, or a pharmaceutically acceptable salt thereof, inassociation with a pharmaceutically acceptable carrier; and

Compound B, or a pharmaceutically acceptable salt thereof, inassociation with a pharmaceutically acceptable carrier.

In one embodiment of the invention the combination kit comprises thefollowing components:

Compound A, or a pharmaceutically acceptable salt thereof, inassociation with a pharmaceutically acceptable carrier; and

Compound B, or a pharmaceutically acceptable salt thereof, inassociation with a pharmaceutically acceptable carrier,

wherein the components are provided in a form which is suitable forsequential, separate and/or simultaneous administration.

In one embodiment the combination kit comprises:

a first container comprising Compound A, or a pharmaceuticallyacceptable salt thereof, in association with a pharmaceuticallyacceptable carrier; and

a second container comprising Compound B, or a pharmaceuticallyacceptable salt thereof, in association with a pharmaceuticallyacceptable carrier, and a container means for containing said first andsecond containers.

The “combination kit” can also be provided by instruction, such asdosage and administration instructions. Such dosage and administrationinstructions can be of the kind that is provided to a doctor, forexample by a drug product label, or they can be of the kind that isprovided by a doctor, such as instructions to a patient.

Unless otherwise defined, in all dosing protocols described herein, theregimen of compounds administered does not have to commence with thestart of treatment and terminate with the end of treatment, it is onlyrequired that the number of consecutive days in which both compounds areadministered and the optional number of consecutive days in which onlyone of the component compounds is administered, or the indicated dosingprotocol—including the amount of compound administered, occur at somepoint during the course of treatment.

As used herein the term “Compound A²” means—Compound A, or apharmaceutically acceptable salt thereof—.

As used herein the term “Compound B²” means—Compound B, or apharmaceutically acceptable salt thereof—.

The term “loading dose” as used herein will be understood to mean asingle dose or short duration regimen of Compound A or Compound B havinga dosage higher than the maintenance dose administered to the subjectto, for example, rapidly increase the blood concentration level of thedrug. Suitably, a short duration regimen for use herein will be from: 1to 14 days; suitably from 1 to 7 days; suitably from 1 to 3 days;suitably for three days; suitably for two days; suitably for one day. Insome embodiments, the “loading dose” can increase the bloodconcentration of the drug to a therapeutically effective level. In someembodiments, the “loading dose” can increase the blood concentration ofthe drug to a therapeutically effective level in conjunction with amaintenance dose of the drug. The “loading dose” can be administeredonce per day, or more than once per day (e.g., up to 4 times per day).Suitably the “loading dose” will be administered once a day. Suitably,the loading dose will be an amount from 2 to 100 times the maintenancedose; suitably from 2 to 10 times; suitably from 2 to 5 times; suitably2 times; suitably 3 times; suitably 4 times; suitably 5 times. Suitably,the loading dose will be administered for from 1 to 7 days; suitablyfrom 1 to 5 days; suitably from 1 to 3 days; suitably for 1 day;suitably for 2 days; suitably for 3 days, followed by a maintenancedosing protocol.

The term “maintenance dose” as used herein will be understood to mean adose that is serially administered (for example; at least twice), andwhich is intended to either slowly raise blood concentration levels ofthe compound to a therapeutically effective level, or to maintain such atherapeutically effective level. The maintenance dose is generallyadministered once per day and the daily dose of the maintenance dose islower than the total daily dose of the loading dose.

Suitably the combinations of this invention are administered within a“specified period”.

By the term “specified period” and derivatives thereof, as used hereinis meant the interval of time between the administration of one ofCompound A² and Compound B² and the other of Compound A² and CompoundB². Unless otherwise defined, the specified period can includesimultaneous administration. When both compounds of the invention areadministered once a day the specified period refers to the timing of theadministration of Compound A² and Compound B² during a single day. Whenone or both compounds of the invention are administered more than once aday, the specified period is calculated based on the firstadministration of each compound on a specific day. All administrationsof a compound of the invention that are subsequent to the first during aspecific day are not considered when calculating the specific period.

Suitably, if the compounds are administered within a “specified period”and not administered simultaneously, they are both administered withinabout 24 hours of each other—in this case, the specified period will beabout 24 hours; suitably they will both be administered within about 12hours of each other—in this case, the specified period will be about 12hours; suitably they will both be administered within about 11 hours ofeach other—in this case, the specified period will be about 11 hours;suitably they will both be administered within about 10 hours of eachother—in this case, the specified period will be about 10 hours;suitably they will both be administered within about 9 hours of eachother—in this case, the specified period will be about 9 hours; suitablythey will both be administered within about 8 hours of each other—inthis case, the specified period will be about 8 hours; suitably theywill both be administered within about 7 hours of each other—in thiscase, the specified period will be about 7 hours; suitably they willboth be administered within about 6 hours of each other—in this case,the specified period will be about 6 hours; suitably they will both beadministered within about 5 hours of each other—in this case, thespecified period will be about 5 hours; suitably they will both beadministered within about 4 hours of each other—in this case, thespecified period will be about 4 hours; suitably they will both beadministered within about 3 hours of each other—in this case, thespecified period will be about 3 hours; suitably they will beadministered within about 2 hours of each other—in this case, thespecified period will be about 2 hours; suitably they will both beadministered within about 1 hour of each other—in this case, thespecified period will be about 1 hour. As used herein, theadministration of Compound A² and Compound B² in less than about 45minutes apart is considered simultaneous administration.

Suitably, when the combination of the invention is administered for a“specified period”, the compounds will be co-administered for a“duration of time”.

By the term “duration of time” and derivatives thereof, as used hereinis meant that both compounds of the invention are administered within a“specified period” for an indicated number of consecutive days,optionally followed by a number of consecutive days where only one ofthe component compounds is administered.

Regarding “specified period” administration:

Suitably, both compounds will be administered within a specified periodfor at least one day—in this case, the duration of time will be at leastone day; suitably, during the course to treatment, both compounds willbe administered within a specified period for at least 3 consecutivedays—in this case, the duration of time will be at least 3 days;suitably, during the course to treatment, both compounds will beadministered within a specified period for at least 5 consecutivedays—in this case, the duration of time will be at least 5 days;suitably, during the course to treatment, both compounds will beadministered within a specified period for at least 7 consecutivedays—in this case, the duration of time will be at least 7 days;suitably, during the course to treatment, both compounds will beadministered within a specified period for at least 14 consecutivedays—in this case, the duration of time will be at least 14 days;suitably, during the course to treatment, both compounds will beadministered within a specified period for at least 30 consecutivedays—in this case, the duration of time will be at least 30 days.

Suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day—in this case,the duration of time will be at least 1 day; suitably, during the courseof treatment, both compounds will be administered within a specifiedperiod for at least 2 consecutive days—in this case, the duration oftime will be at least 2 days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 3 consecutive days—in this case, the duration of time will be atleast 3 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 5consecutive days —in this case, the duration of time will be at least 5days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 7 consecutivedays—in this case, the duration of time will be at least 7 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 14 consecutivedays—in this case, the duration of time will be at least 14 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 30 consecutivedays—in this case, the duration of time will be at least 30 days. When,during the course of treatment, both compounds are administered within aspecified period for over 30 days, the treatment is considered chronictreatment and will continue until an altering event, such as areassessment in cancer status or a change in the condition of thepatient, warrants a modification to the protocol.

Further regarding “specified period” administration:

Suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed bythe administration of Compound A² alone for at least 1 day—in this case,the duration of time will be at least 2 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 1 day, followed by administration ofCompound A² alone for at least 2 days—in this case, the duration of timewill be at least 3 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 1day, followed by administration of Compound A² alone for at least 3days—in this case, the duration of time will be at least 4 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed byadministration of Compound A² alone for at least 4 days—in this case,the duration of time will be at least 5 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 1 day, followed by administration ofCompound A² alone for at least 5 days—in this case, the duration of timewill be at least 6 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 1day, followed by administration of Compound A² alone for at least 6days—in this case, the duration of time will be at least 7 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed byadministration of Compound A² alone for at least 7 days—in this case,the duration of time will be at least 8 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 2 consecutive days, followed byadministration of Compound A² alone for at least 1 day—in this case, theduration of time will be at least 3 days; suitably, during the course oftreatment, both compounds will be administered within a specified periodfor at least 2 consecutive days, followed by administration of CompoundA² alone for at least 2 consecutive days—in this case, the duration oftime will be at least 4 days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 2 consecutive days, followed by administration of Compound A²alone for at least 3 consecutive days—in this case, the duration of timewill be at least 5 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 2consecutive days, followed by administration of Compound A² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 6 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound A² alone for atleast 5 consecutive days—in this case, the duration of time will be atleast 7 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound A² alone for atleast 6 consecutive days—in this case, the duration of time will be atleast 8 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound A² alone for atleast 7 consecutive days—in this case, the duration of time will be atleast 9 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 3consecutive days, followed by administration of Compound A² alone for atleast 1 day—in this case, the duration of time will be at least 4 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 2consecutive days—in this case, the duration of time will be at least 5days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 3consecutive days—in this case, the duration of time will be at least 6days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 4consecutive days—in this case, the duration of time will be at least 7days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 5consecutive days—in this case, the duration of time will be at least 8days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 6consecutive days—in this case, the duration of time will be at least 9days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound A² alone for at least 7consecutive days—in this case, the duration of time will be at least 10days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 4 consecutive days,followed by administration of Compound A² alone for at least 1 day—inthis case, the duration of time will be at least 5 consecutive days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 4 consecutive days,followed by administration of Compound A² alone for at least 2consecutive days—in this case, the duration of time will be at least 6consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound A² alone for atleast 3 consecutive days—in this case, the duration of time will be atleast 7 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound A² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 8 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound A² alone for atleast 7 consecutive days—in this case, the duration of time will be atleast 11 consecutive days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 5 consecutive days, followed by administration of Compound A²alone for at least 1 day—in this case, the duration of time will be atleast 6 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound A² alone for atleast 2 consecutive days—in this case, the duration of time will be atleast 7 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound A² alone for atleast 3 consecutive days—in this case, the duration of time will be atleast 8 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound A² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 9 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound A² alone for atleast 5 consecutive days—in this case, the duration of time will be atleast 10 consecutive days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 7 consecutive days, followed by administration of Compound A²alone for at least 2 consecutive days—in this case, the duration of timewill be at least consecutive days; suitably, during the course oftreatment, both compounds will be administered within a specified periodfor at least 14 consecutive days, followed by administration of CompoundA² alone for at least 7 consecutive days—in this case, the duration oftime will be at least 21 consecutive days; suitably, during the courseof treatment, both compounds will be administered within a specifiedperiod for at least 30 consecutive days, followed by administration ofCompound A² alone for at least 7 consecutive days—in this case, theduration of time will be at least 37 consecutive days. Suitably, duringthe course of treatment, both compounds will be administered within aspecified period for from 1 to 3 consecutive days, followed byadministration of Compound A² alone for from 3 to 7 consecutive days.Suitably, during the course of treatment, both compounds will beadministered within a specified period for from 3 to 6 consecutive days,followed by administration of Compound A² alone for from 1 to 4consecutive days. Suitably, during the course of treatment, bothcompounds will be administered within a specified period for 5consecutive days, followed by administration of Compound A² alone for 2consecutive days. Suitably, during the course of treatment, bothcompounds will be administered within a specified period for 2consecutive days, followed by administration of Compound A² alone forfrom 3 to 7 consecutive days.

Further regarding “specified period” administration:

Suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed bythe administration of Compound B² alone for at least 1 day—in this case,the duration of time will be at least 2 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 1 day, followed by administration ofCompound B² alone for at least 2 days—in this case, the duration of timewill be at least 3 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 1day, followed by administration of Compound B² alone for at least 3days—in this case, the duration of time will be at least 4 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed byadministration of Compound B² alone for at least 4 days—in this case,the duration of time will be at least 5 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 1 day, followed by administration ofCompound B² alone for at least 5 days—in this case, the duration of timewill be at least 6 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 1day, followed by administration of Compound B² alone for at least 6days—in this case, the duration of time will be at least 7 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 1 day, followed byadministration of Compound B² alone for at least 7 days—in this case,the duration of time will be at least 8 days; suitably, during thecourse of treatment, both compounds will be administered within aspecified period for at least 2 consecutive days, followed byadministration of Compound B² alone for at least 1 day—in this case, theduration of time will be at least 3 days; suitably, during the course oftreatment, both compounds will be administered within a specified periodfor at least 2 consecutive days, followed by administration of CompoundB² alone for at least 2 consecutive days—in this case, the duration oftime will be at least 4 days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 2 consecutive days, followed by administration of Compound B²alone for at least 3 consecutive days—in this case, the duration of timewill be at least 5 days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 2consecutive days, followed by administration of Compound B² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 6 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound B² alone for atleast 5 consecutive days—in this case, the duration of time will be atleast 7 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound B² alone for atleast 6 consecutive days—in this case, the duration of time will be atleast 8 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 2consecutive days, followed by administration of Compound B² alone for atleast 7 consecutive days—in this case, the duration of time will be atleast 9 days; suitably, during the course of treatment, both compoundswill be administered within a specified period for at least 3consecutive days, followed by administration of Compound B² alone for atleast 1 day—in this case, the duration of time will be at least 4 days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 2consecutive days—in this case, the duration of time will be at least 5days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 3consecutive days—in this case, the duration of time will be at least 6days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 4consecutive days—in this case, the duration of time will be at least 7days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 5consecutive days—in this case, the duration of time will be at least 8days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 6consecutive days—in this case, the duration of time will be at least 9days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 3 consecutive days,followed by administration of Compound B² alone for at least 7consecutive days—in this case, the duration of time will be at least 10days; suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 4 consecutive days,followed by administration of Compound B² alone for at least 1 day—inthis case, the duration of time will be at least 5 consecutive days;suitably, during the course of treatment, both compounds will beadministered within a specified period for at least 4 consecutive days,followed by administration of Compound B² alone for at least 2consecutive days—in this case, the duration of time will be at least 6consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound B² alone for atleast 3 consecutive days—in this case, the duration of time will be atleast 7 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound B² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 8 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 4consecutive days, followed by administration of Compound B² alone for atleast 7 consecutive days—in this case, the duration of time will be atleast 11 consecutive days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 5 consecutive days, followed by administration of Compound B²alone for at least 1 day—in this case, the duration of time will be atleast 6 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound B² alone for atleast 2 consecutive days—in this case, the duration of time will be atleast 7 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound B² alone for atleast 3 consecutive days—in this case, the duration of time will be atleast 8 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound B² alone for atleast 4 consecutive days—in this case, the duration of time will be atleast 9 consecutive days; suitably, during the course of treatment, bothcompounds will be administered within a specified period for at least 5consecutive days, followed by administration of Compound B² alone for atleast 5 consecutive days—in this case, the duration of time will be atleast 10 consecutive days; suitably, during the course of treatment,both compounds will be administered within a specified period for atleast 7 consecutive days, followed by administration of Compound B²alone for at least 2 consecutive days—in this case, the duration of timewill be at least 9 consecutive days; suitably, during the course oftreatment, both compounds will be administered within a specified periodfor at least 14 consecutive days, followed by administration of CompoundB² alone for at least 7 consecutive days—in this case, the duration oftime will be at least 21 consecutive days; suitably, during the courseof treatment, both compounds will be administered within a specifiedperiod for at least 30 consecutive days, followed by administration ofCompound B² alone for at least 7 consecutive days—in this case, theduration of time will be at least 37 consecutive days. Suitably, duringthe course of treatment, both compounds will be administered within aspecified period for from 1 to 3 consecutive days, followed byadministration of Compound B² alone for from 3 to 7 consecutive days.Suitably, during the course of treatment, both compounds will beadministered within a specified period for from 3 to 6 consecutive days,followed by administration of Compound B² alone for from 1 to 4consecutive days. Suitably, during the course of treatment, bothcompounds will be administered within a specified period for 5consecutive days, followed by administration of Compound B² alone for 2consecutive days. Suitably, during the course of treatment, bothcompounds will be administered within a specified period for 2consecutive days, followed by administration of Compound B² alone forfrom 3 to 7 consecutive days.

Further regarding “specified period” administration:

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for from 1 to 3 days overa 7 day period, and during the other days of the 7 day period CompoundA² will be administered alone. Suitably, this 7 day protocol is repeatedfor 2 cycles or for 14 days; suitably for 4 cycles or 28 days; suitablyfor continuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for from 1 to 3 days overa 7 day period, and during the other days of the 7 day period CompoundB² will be administered alone. Suitably, this 7 day protocol is repeatedfor 2 cycles or for 14 days; suitably for 4 cycles or 28 days; suitablyfor continuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 3 days over a 7 dayperiod, and during the other days of the 7 day period Compound A² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 3 days over a 7 dayperiod, and during the other days of the 7 day period Compound B² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 2 days over a 7 dayperiod, and during the other days of the 7 day period Compound A² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 2 days over a 7 dayperiod, and during the other days of the 7 day period Compound B² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 1 day during a 7 dayperiod, and during the other days of the 7 day period Compound A² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for 1 day during a 7 dayperiod, and during the other days of the 7 day period Compound B² willbe administered alone. Suitably, this 7 day protocol is repeated for 2cycles or for 14 days; suitably for 4 cycles or 28 days; suitably forcontinuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for from 1 to 5 days overa 14 day period, and during the other days of the 14 day period CompoundA² will be administered alone.

Suitably, this 14 day protocol is repeated for 2 cycles or for 28 days;suitably for continuous administration.

Suitably, during the course of treatment, Compound A² and Compound B²will be administered within a specified period for from 1 to 5 days overa 14 day period, and during the other days of the 14 day period CompoundB² will be administered alone.

Suitably, this 14 day protocol is repeated for 2 cycles or for 28 days;suitably for continuous administration.

Suitably, if the compounds are not administered during a “specifiedperiod”, they are administered sequentially. By the term “sequentialadministration”, and derivates thereof, as used herein is meant that oneof Compound A² and Compound B² is administered for two or moreconsecutive days and the other of Compound A² and Compound B² issubsequently administered for two or more consecutive days. Also,contemplated herein is a drug holiday utilized between the sequentialadministration of one of Compound A² and Compound B² and the other ofCompound A² and Compound B². As used herein, a drug holiday is a periodof days after the sequential administration of one of Compound A² andCompound B² and before the administration of the other of Compound A²and Compound B² where neither Compound A² nor Compound B² isadministered. Suitably the drug holiday will be a period of daysselected from: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8days, 9 days, 10 days, 11 days, 12 days, 13 days and 14 days.

Suitably, if the compounds are not administered during a “specifiedperiod”, they are administered sequentially. By the term “sequentialadministration”, and derivates thereof, as used herein is meant that oneof Compound A² and Compound B² is administered once a day for one ormore consecutive days and the other of Compound A² and Compound B² issubsequently administered once a day for one or more consecutive days.Also, contemplated herein is a drug holiday utilized between thesequential administration of one of Compound A² and Compound B² and theother of Compound A² and Compound B². As used herein, a drug holiday isa period of days after the sequential administration of one of CompoundA² and Compound B² and before the administration of the other ofCompound A² and Compound B² where neither Compound A² nor Compound B² isadministered. Suitably the drug holiday will be a period of daysselected from: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8days, 9 days, 10 days, 11 days, 12 days, 13 days and 14 days.

Regarding sequential administration:

Suitably, one of Compound A² and Compound B² is administered for from 2to 30 consecutive days, followed by an optional drug holiday, followedby administration of the other of Compound A² and Compound B² for from 2to 30 consecutive days. Suitably, one of Compound A² and Compound B² isadministered for from 2 to 21 consecutive days, followed by an optionaldrug holiday, followed by administration of the other of Compound A² andCompound B² for from 2 to 21 consecutive days. Suitably, one of CompoundA² and Compound B² is administered for from 2 to 14 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of the other of Compound A² and Compound B² for from 2 to14 consecutive days. Suitably, one of Compound A² and Compound B² isadministered for from 3 to 7 consecutive days, followed by a drugholiday of from 3 to 10 days, followed by administration of the other ofCompound A² and Compound B² for from 3 to 7 consecutive days.

Suitably, one of Compound A² and Compound B² is administered for from 1to 30 consecutive days, followed by an optional drug holiday, followedby administration of the other of Compound A² and Compound B² for from 1to 30 consecutive days. Suitably, one of Compound A² and Compound B² isadministered for from 1 to 21 consecutive days, followed by an optionaldrug holiday, followed by administration of the other of Compound A² andCompound B² for from 1 to 21 consecutive days. Suitably, one of CompoundA² and Compound B² is administered for from 1 to 14 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of the other of Compound A² and Compound B² for from 1 to14 consecutive days. Suitably, one of Compound A² and Compound B² isadministered for from 2 to 7 consecutive days, followed by a drugholiday of from 2 to 10 days, followed by administration of the other ofCompound A² and Compound B² for from 2 to 7 consecutive days.

Suitably, Compound B² will be administered first in the sequence,followed by an optional drug holiday, followed by administration ofCompound A². Suitably, Compound B² is administered for from 3 to 21consecutive days, followed by an optional drug holiday, followed byadministration of Compound A² for from 3 to 21 consecutive days.Suitably, Compound B² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of Compound A² for from 3 to 21 consecutive days.Suitably, Compound B² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 3 to 14 days, followed byadministration of Compound A² for from 3 to 21 consecutive days.Suitably, Compound B² is administered for 21 consecutive days, followedby an optional drug holiday, followed by administration of Compound A²for 14 consecutive days. Suitably, Compound B² is administered for 14consecutive days, followed by a drug holiday of from 1 to 14 days,followed by administration of Compound A² for 14 consecutive days.Suitably, Compound B² is administered for 7 consecutive days, followedby a drug holiday of from 3 to 10 days, followed by administration ofCompound A² for 7 consecutive days. Suitably, Compound B² isadministered for 3 consecutive days, followed by a drug holiday of from3 to 14 days, followed by administration of Compound A² for 7consecutive days. Suitably, Compound B² is administered for 3consecutive days, followed by a drug holiday of from 3 to 10 days,followed by administration of Compound A² for 3 consecutive days.

Suitably, Compound B² will be administered first in the sequence,followed by an optional drug holiday, followed by administration ofCompound A². Suitably, Compound B² is administered for from 1 to 21consecutive days, followed by an optional drug holiday, followed byadministration of Compound A² for from 1 to 21 consecutive days.Suitably, Compound B² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of Compound A² for from 3 to 21 consecutive days.Suitably, Compound B² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 3 to 14 days, followed byadministration of Compound A² for from 3 to 21 consecutive days.Suitably, Compound B² is administered for 21 consecutive days, followedby an optional drug holiday, followed by administration of Compound A²for 14 consecutive days. Suitably, Compound B² is administered for 14consecutive days, followed by a drug holiday of from 1 to 14 days,followed by administration of Compound A² for 14 consecutive days.Suitably, Compound B² is administered for 7 consecutive days, followedby a drug holiday of from 3 to 10 days, followed by administration ofCompound A² for 7 consecutive days. Suitably, Compound B² isadministered for 3 consecutive days, followed by a drug holiday of from3 to 14 days, followed by administration of Compound A² for 7consecutive days. Suitably, Compound B² is administered for 3consecutive days, followed by a drug holiday of from 3 to 10 days,followed by administration of Compound A² for 3 consecutive days.

Suitably, Compound A² will be administered first in the sequence,followed by an optional drug holiday, followed by administration ofCompound B². Suitably, Compound A² is administered for from 3 to 21consecutive days, followed by an optional drug holiday, followed byadministration of Compound B² for from 3 to 21 consecutive days.Suitably, Compound A² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of Compound B² for from 3 to 21 consecutive days.Suitably, Compound A² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 3 to 14 days, followed byadministration of Compound B² for from 3 to 21 consecutive days.Suitably, Compound A² is administered for 21 consecutive days, followedby an optional drug holiday, followed by administration of Compound B²for 14 consecutive days. Suitably, Compound A² is administered for 14consecutive days, followed by a drug holiday of from 1 to 14 days,followed by administration of Compound B² for 14 consecutive days.Suitably, Compound A² is administered for 7 consecutive days, followedby a drug holiday of from 3 to 10 days, followed by administration ofCompound B² for 7 consecutive days. Suitably, Compound A² isadministered for 3 consecutive days, followed by a drug holiday of from3 to 14 days, followed by administration of Compound B² for 7consecutive days. Suitably, Compound A² is administered for 3consecutive days, followed by a drug holiday of from 3 to 10 days,followed by administration of Compound B² for 3 consecutive days.

Suitably, Compound A² will be administered first in the sequence,followed by an optional drug holiday, followed by administration ofCompound B². Suitably, Compound A² is administered for from 1 to 21consecutive days, followed by an optional drug holiday, followed byadministration of Compound B² for from 1 to 21 consecutive days.Suitably, Compound A² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 1 to 14 days, followed byadministration of Compound B² for from 3 to 21 consecutive days.Suitably, Compound A² is administered for from 3 to 21 consecutive days,followed by a drug holiday of from 3 to 14 days, followed byadministration of Compound B² for from 3 to 21 consecutive days.Suitably, Compound A² is administered for 21 consecutive days, followedby an optional drug holiday, followed by administration of Compound B²for 14 consecutive days. Suitably, Compound A² is administered for 14consecutive days, followed by a drug holiday of from 1 to 14 days,followed by administration of Compound B² for 14 consecutive days.Suitably, Compound A² is administered for 7 consecutive days, followedby a drug holiday of from 3 to 10 days, followed by administration ofCompound B² for 7 consecutive days. Suitably, Compound A² isadministered for 3 consecutive days, followed by a drug holiday of from3 to 14 days, followed by administration of Compound B² for 7consecutive days. Suitably, Compound A² is administered for 3consecutive days, followed by a drug holiday of from 3 to 10 days,followed by administration of Compound B² for 3 consecutive days.Suitably, Compound A² is administered for 7 consecutive days, followedby administration of Compound B² for 1 day. Suitably, Compound A² isadministered for 6 consecutive days, followed by administration ofCompound B² for 1 day. Suitably, Compound B² is administered for 1 day,followed by administration of Compound A² for 7 consecutive days.Suitably, Compound B² is administered for 1 day, followed byadministration of Compound A² for 6 consecutive days.

It is understood that a “specified period” administration and a“sequential” administration can be followed by repeat dosing or can befollowed by an alternate dosing protocol, and a drug holiday may precedethe repeat dosing or alternate dosing protocol.

Suitably, the amount of Compound A² administered as part of thecombination according to the present invention will be an amountselected from about 10 mg to about 300 mg; suitably, the amount will beselected from about 30 mg to about 280 mg; suitably, the amount will beselected from about 40 mg to about 260 mg; suitably, the amount will beselected from about 60 mg to about 240 mg; suitably, the amount will beselected from about 80 mg to about 220 mg; suitably, the amount will beselected from about 90 mg to about 210 mg; suitably, the amount will beselected from about 100 mg to about 200 mg, suitably, the amount will beselected from about 110 mg to about 190 mg, suitably, the amount will beselected from about 120 mg to about 180 mg, suitably, the amount will beselected from about 130 mg to about 170 mg, suitably, the amount will beselected from about 140 mg to about 160 mg, suitably, the amount will be150 mg. Accordingly, the amount of Compound A² administered as part ofthe combination according to the present invention will be an amountselected from about 10 mg to about 300 mg. For example, the amount ofCompound A² administered as part of the combination according to thepresent invention is suitably selected from 10 mg, 20 mg, 30 mg, 40 mg,50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg,115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg,160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg,205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg,250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg,295 mg and 300 mg. Suitably, the selected amount of Compound A² isadministered from 1 to 4 times a day. Suitably, the selected amount ofCompound A² is administered twice a day. Suitably, the selected amountof Compound A² is administered once a day. Suitably, the administrationof Compound A² will begin as a loading dose. Suitably, the loading dosewill be an amount from 2 to 100 times the maintenance dose; suitablyfrom 2 to 10 times; suitably from 2 to 5 times; suitably 2 times;suitably 3 times; suitably 4 times; suitably 5 times. Suitably, theloading does will be administered from 1 to 7 days; suitably from 1 to 5days; suitably from 1 to 3 days; suitably for 1 day; suitably for 2days; suitably for 3 days, followed by a maintenance dosing protocol.

Suitably, the amount of Compound B² administered as part of thecombination according to the present invention will be an amountselected from about 5 mg to about 500 mg; suitably, the amount will beselected from about 25 mg to about 400 mg; suitably, the amount will beselected from about 30 mg to about 375 mg; suitably, the amount will beselected from about 35 mg to about 350 mg; suitably, the amount will beselected from about 40 mg to about 300 mg; suitably, the amount will beselected from about 45 mg to about 275 mg; suitably, the amount will beselected from about 50 mg to about 250 mg; suitably, the amount will beselected from about 55 mg to about 225 mg; suitably, the amount will beselected from about 60 mg to about 200 mg; suitably, the amount will beselected from about 65 mg to about 175 mg; suitably, the amount will beselected from about 70 mg to about 150 mg; suitably, the amount will beselected from about 50 mg to about 300 mg; suitably, the amount will beselected from about 75 mg to about 150 mg; suitably, the amount will beabout 100 mg. Accordingly, the amount of Compound B² administered aspart of the combination according to the present invention will be anamount selected from about 5 mg to about 500 mg. For example, the amountof Compound B² administered as part of the combination according to thepresent invention can be 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg,40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135mg, 140 mg, 145 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg or 500 mg.Suitably, the selected amount of Compound B² is administered twice aday. Suitably, the selected amount of Compound B² is administered once aday. Suitably, the administration of Compound A² will begin as a loadingdose. Suitably, the loading dose will be an amount from 2 to 100 timesthe maintenance dose; suitably from 2 to 10 times; suitably from 2 to 5times; suitably 2 times; suitably 3 times; suitably 4 times; suitably 5times. Suitably, the loading does will be administered from 1 to 7 days;suitably from 1 to 5 days; suitably from 1 to 3 days; suitably for 1day; suitably for 2 days; suitably for 3 days, followed by a maintenancedosing protocol.

Suitably, the amount of Compound B² administered as part of thecombination according to the present invention will be an amountselected from about 75 mg to about 1,000 mg; suitably, the amount willbe selected from about 100 mg to about 900 mg; suitably, the amount willbe selected from about 150 mg to about 850 mg; suitably, the amount willbe selected from about 200 mg to about 800 mg; suitably, the amount willbe selected from about 250 mg to about 750 mg; suitably, the amount willbe selected from about 300 mg to about 6000 mg; suitably, the amountwill be about 450 mg. Accordingly, the amount of Compound B²administered as part of the combination according to the presentinvention will be an amount selected from about 75 mg to about 1,000 mg.For example, the amount of Compound B² administered as part of thecombination according to the present invention can be 75 mg, 100 mg, 125mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg or 1,000 mg.Suitably, the selected amount of Compound B² is administered twice aday. Suitably, the selected amount of Compound B² is administered once aday.

As used herein, all amounts specified for Compound A² and Compound B²are indicated as the administered amount of free or unsalted andunsolvated compound per dose.

The method of the present invention may also be employed with othertherapeutic methods of cancer treatment.

While it is possible that, for use in therapy, therapeutically effectiveamounts of the combinations of the present invention may be administeredas the raw chemical, it is preferable to present the combinations as apharmaceutical composition or compositions. Accordingly, the inventionfurther provides pharmaceutical compositions, which include Compound A²and/or Compound B², and one or more pharmaceutically acceptablecarriers. The combinations of the present invention are as describedabove. The carrier(s) must be acceptable in the sense of beingcompatible with the other ingredients of the formulation, capable ofpharmaceutical formulation, and not deleterious to the recipientthereof. In accordance with another aspect of the invention there isalso provided a process for the preparation of a pharmaceuticalformulation including admixing Compound A² and/or Compound B² with oneor more pharmaceutically acceptable carriers. As indicated above, suchelements of the pharmaceutical combination utilized may be presented inseparate pharmaceutical compositions or formulated together in onepharmaceutical formulation.

Pharmaceutical formulations may be presented in unit dose formscontaining a predetermined amount of active ingredient per unit dose. Asis known to those skilled in the art, the amount of active ingredientper dose will depend on the condition being treated, the route ofadministration and the age, weight and condition of the patient.Preferred unit dosage formulations are those containing a daily dose orsub-dose, or an appropriate fraction thereof, of an active ingredient.Furthermore, such pharmaceutical formulations may be prepared by any ofthe methods well known in the pharmacy art.

Compound A² and Compound B² may be administered by any appropriateroute. Suitable routes include oral, rectal, nasal, topical (includingbuccal and sublingual), vaginal, and parenteral (including subcutaneous,intramuscular, intravenous, intradermal, intrathecal, and epidural). Itwill be appreciated that the preferred route may vary with, for example,the condition of the recipient of the combination and the cancer to betreated. It will also be appreciated that each of the agentsadministered may be administered by the same or different routes andthat Compound A² and Compound B² may be compounded together in apharmaceutical composition/formulation.

The compounds or combinations of the current invention are incorporatedinto convenient dosage forms such as capsules, tablets, or injectablepreparations. Solid or liquid pharmaceutical carriers are employed.Solid carriers include, starch, lactose, calcium sulfate dihydrate,terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesiumstearate, and stearic acid. Liquid carriers include syrup, peanut oil,olive oil, saline, and water. Similarly, the carrier may include aprolonged release material, such as glyceryl monostearate or glyceryldistearate, alone or with a wax. The amount of solid carrier varieswidely but, preferably, will be from about 25 mg to about 1 g per dosageunit. When a liquid carrier is used, the preparation will suitably be inthe form of a syrup, elixir, emulsion, soft gelatin capsule, sterileinjectable liquid such as an ampoule, or an aqueous or nonaqueous liquidsuspension.

For instance, for oral administration in the form of a tablet orcapsule, the active drug component can be combined with an oral,non-toxic pharmaceutically acceptable inert carrier such as ethanol,glycerol, water and the like. Powders are prepared by comminuting thecompound to a suitable fine size and mixing with a similarly comminutedpharmaceutical carrier such as an edible carbohydrate, as, for example,starch or mannitol. Flavoring, preservative, dispersing and coloringagent can also be present.

It should be understood that in addition to the ingredients mentionedabove, the formulations may include other agents conventional in the arthaving regard to the type of formulation in question, for example thosesuitable for oral administration may include flavoring agents.

As indicated, therapeutically effective amounts of the combinations ofthe invention (Compound A² in combination with Compound B²) areadministered to a human. Typically, the therapeutically effective amountof the administered agents of the present invention will depend upon anumber of factors including, for example, the age and weight of thesubject, the precise condition requiring treatment, the severity of thecondition, the nature of the formulation, and the route ofadministration. Ultimately, the therapeutically effective amount will beat the discretion of the attendant physician.

The combinations of the present invention are tested for efficacy,advantageous and synergistic properties according to known procedures.

Suitably, the combinations of the invention are tested for efficacy,advantageous and synergistic properties generally according to thefollowing combination cell proliferation assays. Cells are plated in384-well plates at 500 cells/well in culture media appropriate for eachcell type, supplemented with 10% FBS and 1% penicillin/streptomycin, andincubated overnight at 37° C., 5% CO₂. Cells are treated in a gridmanner with dilution of Compound A² (20 dilutions, including nocompound, of 2-fold dilutions starting from 1-20 μM depending oncombination) from left to right on 384-well plate and also treated withCompound B² (20 dilutions, including no compound, of 2-fold dilutionsstarting from 1-20 μM depending on combination) from top to bottom on384-well plate and incubated as above for a further 72 hours. In someinstances compounds are added in a staggered manner and incubation timecan be extended up to 7 days. Cell growth is measured usingCellTiter-Glo® reagent according to the manufacturer's protocol andsignals are read on a PerkinElmer EnVision™ reader set for luminescencemode with a 0.5-second read. Data are analyzed as described below.

Results are expressed as a percentage of the t=0 value and plottedagainst compound(s) concentration. The t=0 value is normalized to 100%and represents the number of cells present at the time of compoundaddition. The cellular response is determined for each compound and/orcompound combination using a 4- or 6-parameter curve fit of cellviability against concentration using the IDBS XLfit plug-in forMicrosoft Excel software and determining the concentration required for50% inhibition of cell growth (glC₅₀). Background correction is made bysubtraction of values from wells containing no cells. For each drugcombination a Combination Index (CI), Excess Over Highest Single Agent(EOHSA) and Excess Over Bliss (EOBliss) are calculated according toknown methods such as described in Chou and Talalay (1984) Advances inEnzyme Regulation, 22, 37 to 55; and Berenbaum, M C (1981) Adv. CancerResearch, 35, 269-335.

In Vitro Combination Studies of BRAF and AKT Inhibitors on Cancer CellsLines from Multiple Origins Encoding Different Mutations within the MAPKand AKT/PI3K Pathways

Drug combinations experiments were carried out in 384-well plates. Cellwere plated in 384-well plates at 500 cells/well in culture mediaappropriate for each cell type, supplemented with 10% FBS and 1%penicillin/streptomycin, and incubated overnight at 37° C., 5% CO₂.Sixteen concentrations of 2 folds dilution of each drug were tested inmatrix for cell growth inhibition. Concentrations tested for theCompound A (BRAF compound) and Compound B (AKT compound) were 10 μM-0.3nM. Cells were treated with compound combination and incubated at 37° C.for 72 hours. Cell growth was measured using CellTiter-Glo® reagentaccording to the manufacturer's protocol and signals were read on aPerkinElmer EnVision™ reader set for luminescence mode with a 0.5-secondread. Results are expressed as a percentage inhibition compared to DMSOtreated cells and background correction was made by subtraction ofvalues from wells containing no cells.

The response (percent inhibition compared to untreated samples andnormalized to media alone) of compound “A” at “a” concentration (Ra) andthat of compound “B” at “b” concentration (Rb) is compared to responseof the mixture of compounds “A” and “B” at concentrations “a” and “b”respectively (Rab). The equation for EOHSA is:

Rab>10% of the higher value among Ra and Rb=additive

Rab<−10% of the higher value among Ra and Rb=antagonism

Using this formula, if Rab is greater by 10% or more than the highestvalue between Ra and Rb the drug combination is additive. If Rab issmaller by 10% or more than the highest value between Ra and Rb the drugcombination is antagonistic.

The number of combinations in the 16×16 matrix responding in an additivemanner to the combination treatment were enumerated and summarized inTable 1. On this table we assigned a combination on a given cell line tobe beneficial (gray square) if more than 20% (51 combination out of 256tested) of combinations tested showed additivity as defined by a valuegreater than 10% Excess Over the Highest Single Agent (10% EOHSA).

TABLE 1 Combination effect of AKT and BRAF inhibitors on multiple cancercell lines.

These data demonstrate that the combination of AKT and BRAF inhibitorsis favorable on multiple cancer cell lines from multiple originsindependent of the mutational status of key oncogenes within the MAPK orthe AKT/PI3K pathways as multiple drug combinations (>20%) showedinhibitory activity >10% Excess Over Highest Single Agent (EOHSA).

In Vitro Cell Growth Inhibition by Compound A (BRAF Compound), CompoundB (AKT Compound), and their Combination in Tumor Cell Lines

Methods:

Cell Lines and Growth Conditions

Human colon tumor lines, Colo205, DLD1, HCC2998, HCT15, HCT8, HT29,KM-12, LS1034, LS174T, NCI-H508, RKO, SW1417, SW1463, SW480, SW837 andT84, and human melanoma line A375 were from ATCC. A375PF11 was derivedfrom A375, 12R5-1, 12R5-3, 12R8-1, 12R8-3, 16R5-2, 16R6-3 and 16R6-4 aresingle cell clones derived from mixed populations of A375PF11 cells thatwere selected to grow in Compound A to concentrations of 1200 and 1600nM. All lines were cultured in RPMI 1640 medium containing 10% fetalbovine serum (FBS).

Cell Growth Inhibition Assay and Combination Data Analysis.

All cells were cultured for a minimum of 72 hours prior to cell plating.Cells were assayed in a 96-well tissue culture plate (NUNC 136102) ofRPMI medium containing 10% FBS for all cells at 1,000 cells per well.Approximately 24 hours after plating, cells were exposed to ten,three-fold serial dilutions of compound or the combination of the twoagents at a constant molar to molar ratio of 1:10 Compound A to CompoundB in RPMI media containing 10% FBS. Cells were incubated in the presenceof compounds for 3 days. ATP levels were determined by adding Cell TiterGlo® (Promega) according to the manufacturer's protocol. Briefly, CellTiter Glo® was added each plate, incubated for 30 minutes thenluminescent signal was read on the SpectraMax L plate reader with a 0.5sec integration time.

Inhibition of cell growth was estimated after treatment with compound orcombination of compounds for three days and comparing the signal tocells treated with vehicle (DMSO). Cell growth was calculated relativeto vehicle (DMSO) treated control wells. Concentration of compound thatinhibits 50% of control cell growth (IC₅₀) was interpolated when y=50%of the vehicle control using nonlinear regression with the equation,y=(A+(B−A)/(1+(C/x)^D))), where A is the minimum response (y_(min)), Bis the maximum response (y_(max)), C is the inflection point of thecurve (EC₅₀) and D is the Hill coefficient.

Combination effects on potency were evaluated using Combination Index(CI) which was calculated with the back-interpolated IC₅₀ values and themutually non-exclusive equation derived by Chou and Talalay (1):CI=Da/IC ₅₀(a)+Db/IC ₅₀(b)+(Da×Db)/(IC ₅₀(a)×IC ₅₀(b))

where IC₅₀(a) is the IC₅₀ of Compound A; IC₅₀(b) is the IC₅₀ forCompound B; Da is the concentration of Compound A in combination withCompound B that inhibited 50% of cell growth; and Db is theconcentration of Compound B in combination with Compound A thatinhibited 50% of cell growth. In general, a CI value <0.9, between 0.9and 1.1, or >1.1 indicates synergy, additivity and antagonism,respectively. In general, the smaller the CI number, the greater is thestrength of synergy.

The combination effects on the response scale were quantified by ExcessOver Highest Single Agent (EOHSA) based on the concept of nonlinearblending as described in detail by Peterson and Novick (2007) andPeterson (2010) [(2;3) [Peterson and Novick, 2007; Peterson, 2010].EOHSA values are defined as increases in improvement (here, in‘percentage points’ (ppts) difference) produced by the combination overthe best single agent at its component dose level for the combination.For single agent and combination treatments, cells were exposed tocompounds at a fixed-dose-ratio, and dose response curves were fit tothe experimental data and analyzed using regression models. At specifiedtotal dose levels of IC₅₀ along the dose response curve, the dosecombination (corresponding to IC₅₀) was determined for making EOHSAstatistical inferences. More specifically, for a combination drugexperiment involving drug 1 at dose d1 and drug 2 at dose d2, (i.e.,total dose equals d1+d2) is said to have a positive EOHSA if the meanresponse at the combination is better than the mean response to drug 1at dose d1 or drug 2 at dose d2.

Results:

The effect of cell growth inhibition by a BRAF inhibitor Compound A, anAKT inhibitor Compound B and their combination was determined in a panelof human tumor cell lines. The mean IC₅₀s (from at least two independentexperiments) and the combination effects at IC₅₀s are summarized inTable 2 with BRAF, KRAS and PIK3CA mutation status.

The four colon cell lines with BRAF V600E mutation displayed sensitivityto Compound A with IC50 values between 0.018 μM and 3.316 μM, and toCompound B with IC₅₀ values between 0.290 μM and 2.587 μM. Thecombination of Compound A and Compound B was highly synergistic with CIvalue of 0.16 in RKO cells with mutations of both BRAF V600E and PIK3CAH1047R, and moderately synergistic or additive in SW1417, Colo205 andHT29 lines. The other 12 colon lines without BRAF V600E mutation wereinsensitive to Compound A (IC₅₀s>5 μM). The combination of Compound Aand Compound B showed enhanced cell growth inhibition demonstrated bythe EOHSA values from 17 to 54 ppts in these lines.

For the melanoma tumor lines listed in Table 2, A375PF11 cells with BRAFV600E mutation were highly sensitive to Compound A (IC₅₀=0.063 μM), butinsensitive to Compound B (IC₅₀>10 μM). The combination of Compound Aand Compound B showed activity similar to Compound A alone in A375PF11cells. The seven Compound A resistant clones (12R8-3, 12R8-1, 12R5-3,16R5-2, 16R6-3, 16R6-4 and 12R5-1 derived from the A375PF11 melanomacell line) were insensitive to Compound B with IC₅₀s≧7 μM. Thecombination of Compound A and Compound B showed enhanced cell growthinhibition at relatively higher concentrations (˜1 μM) of both CompoundA and Compound B.

Table 2. Cell growth inhibition by Compound A, Compound B and theircombination in human tumor cell lines.

TABLE 2 IC50 values in micromolar (mean ± std) Compound A or B at 1:1Mutation Status Single Agent molar ratio Combination Effects Cell LinesBRAF KRAS PIK3CA Compound A Compound B combination CI EOHSA Colon RKOV600E WT H1047R 3.136 ± 3.466 0.290 ± 0.070 0.038 ± 0.012 0.16 ± 0.02 26± 2 SW1417 V600E WT WT 0.101 ± 0.031 2.587 ± 1.757 0.065 ± 0.025 0.69 ±0.03  4 ± 1 HT29 V600E WT P449T 0.028 ± 0.007 0.503 ± 0.073 0.023 ±0.001 0.95 ± 0.27  2 ± 4 Colo205 V600E WT WT 0.018 ± 0.003 0.908 ± 0.6050.017 ± 0.002 0.97 ± 0.01  2 ± 1 NCl-H508 G596R WT E545K >10 0.234 ±0.247 0.103 ± 0.088 N/A  19 ± 11 HCT8 WT G13D E545K >10 0.527 ± 0.0360.236 ± 0.036 N/A 15 ± 2 KM-12 WT WT WT >10 1.412 ± 0.961 0.503 ± 0.266N/A 20 ± 9 HCT15 WT G13D D549N, E545K >10 4.205 ± 0.834 0.610 ± 0.039N/A 38 ± 3 HCC2998 WT A146T WT >10 2.912 ± 1447  0.686 ± 0.043 N/A 21 ±4 DLD1 WT G13D E545K, D549N >10 >10 0.762 ± 0.083 N/A 32 ± 3 LS174T WTG12D H1047R >10 3.746 ± 0.945 0.946 ± 0.202 N/A  39 ± 11 SW480 WT G12CWT >10 5.625 ± 1.853 1.441 ± 1.022 N/A 26 ± 3 LS1034 WT A146T WT >106.393 ± 3.554 1.519 ± 0.524 N/A 17 ± 0 SW1463 WT G12C WT >10 5.230 ±7.396 2.797 ± 2.174 N/A 54 ± 5 SW837 WT G12C WT 5.437 ± 7.689 >10 3.582± 0.554 N/A  25 ± 14 T84 WT G13D E542K >10 >10 5.121 ± 2.507 N/A 50 ± 0Melanoma F11 BRAF_V600E WT NT 0.063 ± 0.004 >10 0.090 ± 0.021 1.443 ±0.245 −5 ± 4 16R5-2 BRAF_V600E WT NT >10 7.050 ± 1.326 0.897 ± 0.071 N/A32 ± 1 16R6-4 BRAF_V600E WT NT >10 >10 1.122 ± 0.083 N/A  41 ± 13 12R5-1BRAF_V600E WT NT >10 >10 1.176 ± 0.014 N/A 65 ± 7 12R5-3 BRAF_V600E WTNT >10 >10 1.229 ± 0.394 N/A  44 ± 20 12R8-3 BRAF_V600E WT NT >10 >101.271 ± 0.142 N/A 55 ± 6 12R8-1 BRAF_V600E WT NT >10 >10 1.667 ± 0.125N/A 45 ± 0 16R6-3 BRAF_V600E WT NT >10 >10 1.720 ± 0.300 N/A 42 ± 5Table 2 Key: IC₅₀: the concentration of Compound(s) or the concentrationof Compound A in the presence of equal molar Compound B that reducescell growth by 50%; CI = Combination Index; N/A = not applicable; NT =not tested. EOHSA: Excess over Highest Single Agent, measured as apercentage. F11: A375PF11.

REFERENCE LIST

-   (1) Chou T C, Talalay P. Quantitative analysis of dose-effect    relationships: the combined effects of multiple drugs or enzyme    inhibitors. Adv Enzyme Regul 1984; 22:27-55.-   (2) Peterson J J, Novick S J. Nonlinear blending: a useful general    concept for the assessment of combination drug synergy. J Recept    Signal Transduct Res 2007; 27(2-3):125-46.-   (3) Peterson J. A Review of Synergy Concepts of Nonlinear Blending    and Dose-Reduction Profiles. Frontiers of Bioscience S2, 483-503.    2010.

Because the combinations of the present invention are active in theabove assays they exhibit advantageous therapeutic utility in treatingcancer.

Suitably, the present invention relates to a method for treating orlessening the severity of a cancer selected from: brain (gliomas),glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonanasyndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatorybreast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma,ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver,melanoma, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giantcell tumor of bone, thyroid,

Lymphoblastic T cell leukemia, Chronic myelogenous leukemia, Chroniclymphocytic leukemia, Hairy-cell leukemia, acute lymphoblastic leukemia,acute myelogenous leukemia, Chronic neutrophilic leukemia, Acutelymphoblastic T cell leukemia, Plasmacytoma, Immunoblastic large cellleukemia, Mantle cell leukemia, Multiple myeloma Megakaryoblasticleukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocyticleukemia, Erythroleukemia,

malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma,lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma,

neuroblastoma, bladder cancer, urothelial cancer, lung cancer, vulvalcancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma,esophageal cancer, salivary gland cancer, hepatocellular cancer, gastriccancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST(gastrointestinal stromal tumor) and testicular cancer.

Suitably, the present invention relates to a method for treating orlessening the severity of a cancer selected from: brain (gliomas),glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonanasyndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, headand neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate,sarcoma and thyroid.

Suitably, the present invention relates to a method for treating orlessening the severity of a cancer selected from ovarian, breast,pancreatic and prostate.

Suitably the present invention relates to a method for treating orlessening the severity of pre-cancerous syndromes in a mammal, includinga human, wherein the pre-cancerous syndrome is selected from: cervicalintraepithelial neoplasia, monoclonal gammapathy of unknown significance(MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions,skin nevi (pre-melanoma), prostatic intraepithleial (intraductal)neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps andsevere hepatitis or cirrhosis.

Suitably, the present invention relates to a method of treating orlessening the severity of a cancer that is either wild type or mutantfor Raf and either wild type or mutant for PI3K/Pten. This includespatients wild type for both Raf and PI3K/PTEN, mutant for both Raf andPI3K/PTEN, mutant for Raf and wild type for PI3K/PTEN and wild type forRaf and mutant for PI3K/PTEN.

The term “wild type” as is understood in the art refers to a polypeptideor polynucleotide sequence that occurs in a native population withoutgenetic modification. As is also understood in the art, a “mutant”includes a polypeptide or polynucleotide sequence having at least onemodification to an amino acid or nucleic acid compared to thecorresponding amino acid or nucleic acid found in a wild typepolypeptide or polynucleotide, respectively. Included in the term mutantis Single Nucleotide Polymorphism (SNP) where a single base pairdistinction exists in the sequence of a nucleic acid strand compared tothe most prevalently found (wild type) nucleic acid strand.

Cancers that are either wild type or mutant for Raf and either wild typeor mutant for PI3K/Pten are identified by known methods.

For example, wild type or mutant Raf or PI3K/PTEN tumor cells can beidentified by DNA amplification and sequencing techniques, DNA and RNAdetection techniques, including, but not limited to Northern andSouthern blot, respectively, and/or various biochip and arraytechnologies. Wild type and mutant polypeptides can be detected by avariety of techniques including, but not limited to immunodiagnostictechniques such as ELISA, Western blot or immunocyto chemistry.Suitably, Pyrophosphorolysis-activated polymerization (PAP) and/or PCRmethods may be used. Liu, Q et al; Human Mutation 23:426-436 (2004).

This invention provides a combination comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof.

This invention also provides for a combination comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, for use in therapy.

This invention also provides for a combination comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, for use in treatingcancer.

This invention also provides a pharmaceutical composition comprising acombination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof.

This invention also provides a combination kit comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof.

This invention also provides for the use of a combination comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, in the manufacture of amedicament.

This invention also provides for the use of a combination comprisingN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, in the manufacture of amedicament to treat cancer.

This invention also provides a method of treating cancer which comprisesadministering a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide,or a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to a subject in needthereof.

The following examples are intended for illustration only and are notintended to limit the scope of the invention in any way.

EXPERIMENTAL DETAILS Example 1 Capsule Composition

An oral dosage form for administering a combination of the presentinvention is produced by filing a standard two piece hard gelatincapsule with the ingredients in the proportions shown in Table I, below.

TABLE I INGREDIENTS AMOUNTSN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)- 100 mg1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamidemethanesulfonate (the methanesulfonate salt of Compound A)N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5- 300 mgchloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2- furancarboxamide(Compound B) Mannitol 250 mg Talc 125 mg Magnesium Stearate 8 mg

Example 2 Capsule Composition

An oral dosage form for administering one of the compounds of thepresent invention is produced by filing a standard two piece hardgelatin capsule with the ingredients in the proportions shown in TableII, below.

TABLE II INGREDIENTS AMOUNTSN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)- 100 mg1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamidemethanesulfonate (the methanesulfonate salt of Compound A) 55 mgMannitol Talc 16 mg Magnesium Stearate 4 mg

Example 3 Capsule Composition

An oral dosage form for administering one of the compounds of thepresent invention is produced by filing a standard two piece hardgelatin capsule with the ingredients in the proportions shown in TableIII, below.

TABLE III INGREDIENTS AMOUNTSN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}- 300 mg5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2- furancarboxamide(Compound B) Mannitol 250 mg Talc 125 mg Magnesium Stearate 8 mg

Example 4 Tablet Composition

The sucrose, microcrystalline cellulose and the compounds of theinvented combination, as shown in Table IV below, are mixed andgranulated in the proportions shown with a 10% gelatin solution. The wetgranules are screened, dried, mixed with the starch, talc and stearicacid, then screened and compressed into a tablet.

TABLE IV INGREDIENTS AMOUNTSN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)- 100 mg1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamidemethanesulfonate (the methanesulfonate salt of Compound A)N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5- 300 mgchloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2- furancarboxamide(Compound B) Microcrystalline cellulose 300 mg sucrose 10 mg starch 40mg talc 20 mg stearic acid 5 mg

Example 5 Tablet Composition

The sucrose, microcrystalline cellulose and one of the compounds of theinvented combination, as shown in Table V below, are mixed andgranulated in the proportions shown with a 10% gelatin solution. The wetgranules are screened, dried, mixed with the starch, talc and stearicacid, then screened and compressed into a tablet.

TABLE V INGREDIENTS AMOUNTSN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)- 100 mg1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamidemethanesulfonate (the methanesulfonate salt of Compound A)Microcrystalline cellulose 30 mg sucrose 4 mg starch 2 mg talc 1 mgstearic acid 0.5 mg

Example 6 Tablet Composition

The sucrose, microcrystalline cellulose and one of the compounds of theinvented combination, as shown in Table VI below, are mixed andgranulated in the proportions shown with a 10% gelatin solution. The wetgranules are screened, dried, mixed with the starch, talc and stearicacid, then screened and compressed into a tablet.

TABLE VI INGREDIENTS AMOUNTSN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}- 300 mg5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2- furancarboxamide(Compound B) Microcrystalline cellulose 300 mg sucrose 40 mg starch 20mg talc 10 mg stearic acid 5 mg

While the preferred embodiments of the invention are illustrated by theabove, it is to be understood that the invention is not limited to theprecise instructions herein disclosed and that the right to allmodifications coming within the scope of the following claims isreserved.

We claim:
 1. A method of treating a cancer selected from melanoma,breast, colon, lung, and sarcoma in a human in need thereof whichcomprises the in vivo administration of a therapeutically effectiveamount of a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to such human, whereinthe combination is administered within a specified period, and whereinthe combination is administered for a duration of time.
 2. A methodaccording to claim 1 wherein the amount ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, is selected from about 70mg to about 260 mg, and that amount is administered twice per day, andthe amount ofN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, is selected from about 10mg to about 300 mg, and that amount is administered once per day.
 3. Amethod according to claim 1 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for from 1 to 3 consecutive days followed byadministration ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof for from 3 to 7consecutive days, optionally followed by one or more cycles of repeatdosing.
 4. A method of treating a cancer selected from melanoma, breast,colon, lung, and sarcoma that is either wild type or mutant for Raf andeither wild type or mutant for PI3K/PTEN in a human in need thereofwhich comprises the in vivo administration of a therapeuticallyeffective amount of a combination ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, to such human, whereinthe combination is administered within a specified period, and whereinthe combination is administered for a duration of time.
 5. A methodaccording to claim 4 wherein the amount ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, is selected from about 70mg to about 260 mg, and that amount is administered twice per day, andthe amount ofN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable saltthereof, is selected from about 10 mg to about 300 mg, and that amountis administered once per day.
 6. A method according to claim 2 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for 2 days over a 7 day period, and during theother days of the 7 day periodN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, is administered alone,optionally followed by one or more cycles of repeat dosing.
 7. A methodaccording to claim 3 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered withinhours of each other for 2 consecutive days followed by administration ofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, for from 4 to 6consecutive days, optionally followed by one or more cycles of repeatdosing.
 8. A method according to claim 5 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for 2 days over a 7 day period, and during theother days of the 7 day periodN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, is administered alone,optionally followed by one or more cycles of repeat dosing.
 9. A methodaccording to claim 2 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for at least 5 consecutive days.
 10. A methodaccording to claim 5 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for 5 consecutive days followed by administrationofN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, for 2 consecutive days,optionally followed by one or more cycles of repeat dosing.
 11. A methodaccording to claim 5 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for 5 days over a 14 day period, and during theother days of the 14 day periodN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, optionally followed byone or more cycles of repeat dosing.
 12. A method according to claim 5whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered within12 hours of each other for 2 days over a 7 day period, and during theother days of the 7 day periodN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, is administered alone,optionally followed by one or more cycles of repeat dosing.
 13. A methodaccording to claim 5 whereinN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, andN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, are administered withinhours of each other for 5 days over a 14 day period, and during theother days of the 14 day periodN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, is administered alone,optionally followed by one or more cycles of repeat dosing.
 14. A methodaccording to claim 5 wherein the compoundN-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamideor a pharmaceutically acceptable salt thereof, is first administered ina loading dose for from 1 to 3 days followed by maintenance doseadministration of the compound.
 15. A method according to claim 5wherein the compoundN-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide,or a pharmaceutically acceptable salt thereof, is first administered ina loading dose for from 1 to 3 days followed by maintenance doseadministration of the compound.